Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464756 | 0.95 | TLR7 (0.48) | TLR7CYP3A4CYP2D6ADORA2ATMIGD3 | |
| SCHEMBL5465266 | 0.90 | TLR7 (0.50) | TLR7ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL5467042 | 0.87 | TLR7 (0.45) | TLR7CYP3A4CYP2D6ADORA2ATMIGD3 | |
| SCHEMBL5465082 | 0.85 | TLR7 (0.49) | TLR7ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL5458040 | 0.85 | TLR7 (0.60) | TLR7ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL5459639 | 0.83 | TLR7 (0.60) | TLR7ADORA2ATMIGD3ADORA1ADORA2B | |
| SCHEMBL5464924 | 0.83 | ADORA2A (0.45) | TLR7CYP3A4CYP2D6ADORA2ATMIGD3 | |
| SCHEMBL7204649 | 0.81 | TLR7 (0.64) | TLR7ADORA2A | |
| SCHEMBL2060425 | 0.80 | TLR7 (0.54) | TLR7CYP3A4CYP2D6ADORA2AADORA2B | |
| SCHEMBL5163121 | 0.80 | ADORA2A (0.60) | ADORA2ATMIGD3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | TLR7 1/4885CYP3A4 1622/4885CYP2D6 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.